MPN webinar 1: symptom burden and management

What is your MPN patient not telling you? Patient and physician perceptions on the burden of myeloproliferative neoplasms (MPNs).

“The clinical presentation is associated with a substantial disease burden and this often leads to a reduced quality of life for many patients.”

Professor Mary Frances McMullin

 

View webinar 1 breakdown ›

 

 

Prescribing information and adverse event reporting

MPN webinar 2: managing MF in real-world practice

What is REALLY going on in MPNs? Real-world evidence in MPNs.

“We need to have a more objective approach to trying to assess [MPN patients’] symptom burden and making therapeutic decisions.”

Professor Adam Mead

 

View webinar 2 breakdown ›

 

 

MF, myelofibrosis.

Prescribing information and adverse event reporting

MPN webinar 3: the influence of genetic mutations on MPNs

Which MPN patients do I need to really watch? Molecular variables in prognostic models for patients with myeloproliferative neoplasms.

“...particularly in patients with low-risk scores, that you might be comfortable just ‘watching and waiting’, you really should be delving a bit deeper and looking for these mutations, which might influence your approach.”

Dr Mark Drummond

 

View webinar 3 breakdown ›

 

Prescribing information and adverse event reporting

MPN webinar 4: running a virtual clinic: tips and tricks

Setting up a virtual clinic? What are the keys to success, and the pitfalls to avoid? Get advice, tips and tricks from an expert in this setting.

“...change is inevitable and sometimes, with the change, we have to look at what we can do well and what we can improve upon.”

Kirsty Crozier

 

View webinar 4 breakdown ›

 

 

Prescribing information and adverse event reporting

UK | January 2020 | 100484
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]